Javad Saghebi

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet Oncology · 2023 · 199 citations

Medicine, Oncology, Pharmacology +16

Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study

Arun Azad, Mathias Bressel, Hsiang Tan et al. · The Lancet Oncology · 2024 · 111 citations

Medicine, Oncology, Urology +12

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC).

Shahneen Sandhu, Anthony M. Joshua, Louise Emmett et al. · Journal of Clinical Oncology · 2023 · 78 citations

Medicine, Nuclear Medicine, Pharmacology +17

CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC study

Adrian Minson, Nada Hamad, Chan Y. Cheah et al. · Blood · 2023 · 67 citations

Medicine, Hematology, Oncology +17

First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

James P Buteau, Louise Kostos, Price Jackson et al. · The Lancet Oncology · 2025 · 34 citations

Medicine, Nuclear Medicine, Oncology +16